Aarti Pharmalabs profit slides as costs and forex losses mount
Standalone net profit fell to ₹62.03 crore in Q4, down from ₹88.85 crore a year ago, as finance costs and currency headwinds pressured margins.
— 1 earlier story on Aarti Pharmalabs Ltd. →What's new
- Standalone net profit dropped to ₹62.03 cr in Q4 from ₹88.85 cr in the prior year.
- Full-year standalone profit fell to ₹176.20 cr from ₹238.03 cr.
- Margins compressed due to rising finance costs and foreign exchange losses.
Why this matters
Revenue growth is failing to translate into bottom-line performance. The combination of higher interest expenses and forex volatility is eating into profitability, making the margin compression the primary concern for investors.
What we're watching
- Management's plan to mitigate rising finance costs.
- The impact of the previously omitted derivative contract on future cash flows.
- Whether operating margins stabilize in the coming quarters.
The full read
Aarti Pharmalabs reported a sharp decline in standalone profitability for both the fourth quarter and the full year of FY2026. Quarterly net profit fell to ₹62.03 crore, down from ₹88.85 crore in the same period last year. For the full year, profit dropped to ₹176.20 crore from ₹238.03 crore.
Margins are under pressure.
Although revenue from operations grew, the company struggled against rising finance costs and foreign exchange losses that eroded its bottom line. The board recommended a final dividend of ₹2 per share. Audited results include an emphasis of matter concerning a derivative contract that was previously omitted from the financial statements. This is a routine financial release, and the results align with market expectations.
Questions answered
- How did Aarti Pharmalabs perform in FY2026?
- Standalone net profit for the full year declined to ₹176.20 crore, down from ₹238.03 crore in the previous year.
- What caused the decline in profitability?
- While revenue from operations increased, margins were compressed by higher finance costs and foreign exchange losses.
- What is the status of the dividend?
- The board recommended a final dividend of ₹2 per share.
- Are there any specific accounting issues noted in the results?
- The auditors included an emphasis of matter regarding a derivative contract that was previously omitted from the financial statements.
Story so far
All notes on AARTIPHARM →- 25 May 2026 · 9:16 PM IST Aarti Pharmalabs profit slides as costs and forex losses mount
- today Aarti Pharmalabs profit drops as derivative accounting error surfaces